Skip to main content
. 2017 Mar 15;8(39):66540–66549. doi: 10.18632/oncotarget.16239

Figure 2. Kaplan-Meier estimates depicting the recurrence-free survival (a), cancer-specific survival (b), and overall survival (c) stratified according to chronic kidney disease stage 3 (3a vs. 3b).

Figure 2

a. Recurrence-free survival. CKD 3a; median 82.3 (95% CI: not available) vs. CKD 3b; median: not available, p = 0.919. CKD, chronic kidney disease; CI, confidence interval. b. Cancer specific survival. CKD 3a; median: not available vs. CKD 3b; median: not available, p = 0.486. CKD, chronic kidney disease. c. Overall survival. CKD 3a; median: 67.0 months (95% CI: 47.9–not available) vs. CKD 3b; median: 51.3 months (95% CI: 43.7– not available), p = 0.652. CKD, chronic kidney disease; CI, confidence interval.